Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways

PLoS Computational Biology

Volumn 9, Issue 9, 2013, Pages

  Tang, Jing ^a   Karhinen, Leena ^a   Xu, Tao ^a   Szwajda, Agnieszka ^a   Yadav, Bhagwan ^a   Wennerberg, Krister ^a   Aittokallio, Tero ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; CANCER CELLS; CELLS; COST EFFECTIVENESS; DIAGNOSIS; DRUG INTERACTIONS; DRUG THERAPY; FORECASTING;

CANCER CELLS; DRUG COMBINATIONS; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG-RESISTANCE; MULTI-TARGETS; MULTIPLE NODES; POTENTIAL TARGETS; RECENT TRENDS; SYNTHETIC LETHAL;

DISEASES;

ANTINEOPLASTIC AGENT; AURORA B KINASE; AURORA KINASE INHIBITOR; CHIR 265; CRIZOTINIB; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; NILOTINIB; PALBOCICLIB; SMALL INTERFERING RNA; SORAFENIB; TAE 684; UNCLASSIFIED DRUG;

ACCURACY; ALGORITHM; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CALCULATION; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL SURVIVAL; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; NONHUMAN; PREDICTION; SIMULATION; TARGET INHIBITION INFERENCE USING MAXIMIZATION AND MINIMIZATION AVERAGING ALGORITHM; VALIDITY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MODELS, THEORETICAL; NEOPLASMS;

EID: 84884688446     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003226     Document Type: Article

References (61)

1. Pammolli F, Magazzini L, Riccaboni M, (2011) The productivity crisis in pharmaceutical R&D. Nature Reviews Drug Discovery 10: 428-438 doi:10.1038/nrd3405.
2. Hutchinson L, Kirk R, (2011) High drug attrition rates-where are we going wrong? Nature Reviews Clinical Oncology 8: 189-190 doi:10.1038/nrclinonc.2011.34.
3. Hopkins AL, (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4: 682-690 doi:10.1038/nchembio.118.
4. Jia J, Zhu F, Ma X, Cao Z, Cao ZW, et al. (2009) Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8: 111-128 doi:10.1038/nrd2683.
5. Al-Lazikani B, Banerji U, Workman P, (2012) Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 30: 679-692 doi:10.1038/nbt.2284.
6. Ramaswamy S, (2007) Rational design of cancer-drug combinations. N Engl J Med 357: 299-300 doi:10.1056/NEJMcibr072593.
7. Lehár J, Krueger AS, Avery W, Heilbut AM, Johansen LM, et al. (2009) Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 27: 659-666 doi:10.1038/nbt.1549.
8. Dancey JE, Chen HX, (2006) Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 5: 649-659 doi:10.1038/nrd2089.
9. Xie L, Xie L, Kinnings SL, Bourne PE, (2012) Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu Rev Pharmacol Toxicol 52: 361-379 doi:10.1146/annurev-pharmtox-010611-134630.
10. Meyerson M, Gabriel S, Getz G, (2010) Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 11: 685-696 doi:10.1038/nrg2841.
11. Pe'er D, Hacohen N, (2011) Principles and strategies for developing network models in cancer. Cell 144: 864-873 doi:10.1016/j.cell.2011.03.001.
12. Kaelin WG Jr, (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5: 689-698 doi:10.1038/nrc1691.
13. Iglehart JD, Silver DP, (2009) Synthetic lethality-a new direction in cancer-drug development. N Engl J Med 361: 189-191 doi:10.1056/NEJMe0903044.
14. Ashworth A, Lord CJ, Reis-Filho JS, (2011) Genetic Interactions in Cancer Progression and Treatment. Cell 145: 30-38 doi:10.1016/j.cell.2011.03.020.
15. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, et al. (2007) Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446: 815-819 doi:10.1038/nature05697.
16. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137: 835-848 doi:10.1016/j.cell.2009.05.006.
17. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, et al. (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462: 108-112 doi:10.1038/nature08460.
18. Brough R, Frankum JR, Costa-Cabral S, Lord CJ, Ashworth A, (2011) Searching for synthetic lethality in cancer. Curr Opin Genet Dev 21: 34-41 doi:10.1016/j.gde.2010.10.009.
19. Wang Y-Y, Xu K-J, Song J, Zhao X-M, (2012) Exploring drug combinations in genetic interaction network. BMC Bioinformatics 13: S7 doi:10.1186/1471-2105-13-S7-S7.
20. Tang J, Aittokallio T, (2013) Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles. Curr Pharm Des [in press] doi: 10.2174/13816128113199990470.
21. Yang K, Bai H, Ouyang Q, Lai L, Tang C, (2008) Finding multiple target optimal intervention in disease-related molecular network. Mol Syst Biol 4: 228 doi:10.1038/msb.2008.60.
22. Folger O, Jerby L, Frezza C, Gottlieb E, Ruppin E, et al. (2011) Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol 7: 501 doi:10.1038/msb.2011.35.
23. Saadatpour A, Wang R-S, Liao A, Liu X, Loughran TP, et al. (2011) Dynamical and structural analysis of a T cell survival network identifies novel candidate therapeutic targets for large granular lymphocyte leukemia. PLoS Comput Biol 7: e1002267 doi:10.1371/journal.pcbi.1002267.
24. Havaleshko DM, Cho H, Conaway M, Owens CR, Hampton G, et al. (2007) Prediction of drug combination chemosensitivity in human bladder cancer. Mol Cancer Ther 6: 578-586 doi:10.1158/1535-7163.MCT-06-0497.
25. Nelander S, Wang W, Nilsson B, She Q-B, Pratilas C, et al. (2008) Models from experiments: combinatorial drug perturbations of cancer cells. Mol Syst Biol 4: 216 doi:10.1038/msb.2008.53.
26. Lebedeva G, Sorokin A, Faratian D, Mullen P, Goltsov A, et al. (2012) Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network. Eur J Pharm Sci 46: 244-258 doi:10.1016/j.ejps.2011.10.026.
27. Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT, (2010) Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res 70: 6704-6714 doi:10.1158/0008-5472.CAN-10-0460.
28. Jiang H, Pritchard JR, Williams RT, Lauffenburger DA, Hemann MT, (2011) A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat Chem Biol 7: 92-100 doi:10.1038/nchembio.503.
29. Wolpaw AJ, Shimada K, Skouta R, Welsch ME, Akavia UD, et al. (2011) Modulatory profiling identifies mechanisms of small molecule-induced cell death. Proc Natl Acad Sci USA 108: E771-780 doi:10.1073/pnas.1106149108.
30. Pal R, Berlow N, (2012) A kinase inhibition map approach for tumor sensitivity prediction and combination therapy design for targeted drugs. Pac Symp Biocomput pp. 351-362.
31. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607 doi:10.1038/nature11003.
32. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, et al. (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40: D1100-D1107 doi:10.1093/nar/gkr777.
33. Knight ZA, Lin H, Shokat KM, (2010) Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 10: 130-137 doi:10.1038/nrc2787.
34. Pudil P, Ferri FJ, Novovicova J, Kittler J, (1994) Floating search methods for feature selection with nonmonotonic criterion functions. Pattern Recognit 2: 279-283 doi:10.1109/ICPR.1994.576920.
35. Mani R, St Onge RP, Hartman JL4th, Giaever G, Roth FP, (2008) Defining genetic interaction. Proc Natl Acad Sci USA 105: 3461-3466 doi:10.1073/pnas.0712255105.
36. Baryshnikova A, Costanzo M, Kim Y, Ding H, Koh J, et al. (2010) Quantitative analysis of fitness and genetic interactions in yeast on a genome scale. Nat Methods 7: 1017-1024 doi:10.1038/nmeth.1534.
37. Laufer C, Fischer B, Billmann M, Huber W, Boutros M, (2013) Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping. Nat Methods 10: 427-431 doi:10.1038/nmeth.2436.
38. Yeh P, Tschumi AI, Kishony R, (2006) Functional classification of drugs by properties of their pairwise interactions. Nat Genet 38: 489-494 doi:10.1038/ng1755.
39. Cokol M, Chua HN, Tasan M, Mutlu B, Weinstein ZB, et al. (2011) Systematic exploration of synergistic drug pairs. Mol Syst Biol 7: 544 doi:10.1038/msb.2011.71.
40. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132 doi:10.1038/nbt1358.
41. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, et al. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29: 1046-1051 doi:10.1038/nbt.1990.
42. Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, et al. (2013) Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res 73: 285-296 doi:10.1158/0008-5472.CAN-12-1906.
43. Zhu F, Shi Z, Qin C, Tao L, Liu X, et al. (2012) Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res 40: D1128-1136 doi:10.1093/nar/gkr797.
44. Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, et al. (2012) PubChem's BioAssay Database. Nucleic Acids Res 40: D400-412 doi:10.1093/nar/gkr1132.
45. Birmingham A, Selfors LM, Forster T, Wrobel D, Kennedy CJ, et al. (2009) Statistical methods for analysis of high-throughput RNA interference screens. Nat Methods 6: 569-575 doi:10.1038/nmeth.1351.
46. Sharma S, Rao A, (2009) RNAi screening: tips and techniques. Nat Immunol 10: 799-804 doi:10.1038/ni0809-799.
47. Zhang C, Habets G, Bollag G, (2011) Interrogating the kinome. Nature Biotechnology 29: 981-983 doi:10.1038/nbt.2021.
48. Gilot D, Le Meur N, Giudicelli F, Le Vée M, Lagadic-Gossmann D, et al. (2011) RNAi-Based Screening Identifies Kinases Interfering with Dioxin-Mediated Up-Regulation of CYP1A1 Activity. PLoS ONE 6: e18261 doi:10.1371/journal.pone.0018261.
49. Boutros M, Brás LP, Huber W, (2006) Analysis of cell-based RNAi screens. Genome Biol 7: R66 doi:10.1186/gb-2006-7-7-R66.
50. Yang M, Shan B, Li Q, Song X, Cai J, et al. (2013) Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients. Int J Cancer 132: E74-84 doi:10.1002/ijc.27813.
51. Zhang S, Wang F, Keats J, Zhu X, Ning Y, et al. (2011) Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des 78: 999-1005 doi:10.1111/j.1747-0285.2011.01239.x.
52. Dey A, She H, Kim L, Boruch A, Guris DL, et al. (2000) Colony-stimulating factor-1 receptor utilizes multiple signaling pathways to induce cyclin D2 expression. Mol Biol Cell 11: 3835-3848.
53. Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, et al. (2007) Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene 26: 813-821 doi:10.1038/sj.onc.1209843.
54. Yamada S, Nomura T, Takano K, Fujita S, Miyake M, et al. (2008) Expression of a chimeric CSF1R-LTK mediates ligand-dependent neurite outgrowth. Neuroreport 19: 1733-1738 doi:10.1097/WNR.0b013e3283186bf8.
55. Xie L, Kassner M, Munoz RM, Que QQ, Kiefer J, et al. (2012) Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. Biochem Pharmacol 83: 452-461 doi:10.1016/j.bcp.2011.11.005.
56. Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A, et al. (2006) AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene 25: 4831-4839 doi:10.1038/sj.onc.1209494.
57. Holt SV, Logié A, Odedra R, Heier A, Heaton SP, et al. (2012) The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Br J Cancer 106: 858-866 doi:10.1038/bjc.2012.8.
58. Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P, (2010) A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol 6: 343 doi:10.1038/msb.2009.98.
59. Von Eichborn J, Murgueitio MS, Dunkel M, Koerner S, Bourne PE, et al. (2011) PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res 39: D1060-1066 doi:10.1093/nar/gkq1037.
60. Li Z, Wang R-S, Zhang X-S, Chen L, (2009) Detecting drug targets with minimum side effects in metabolic networks. IET Syst Biol 3: 523-533 doi:10.1049/iet-syb.2008.0166.
61. Zhao X-M, Iskar M, Zeller G, Kuhn M, van Noort V, et al. (2011) Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data. PLoS Comput Biol 7: e1002323 doi:10.1371/journal.pcbi.1002323.